Variation d'expression des récepteurs hormonaux et d'HER-2 dans l'évolution du cancer du sein : quelles implications en pratique clinique  [Hormone receptors and HER-2 changes during breast cancer progression: clinical implications].

Détails

ID Serval
serval:BIB_13D9B169E41C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Variation d'expression des récepteurs hormonaux et d'HER-2 dans l'évolution du cancer du sein : quelles implications en pratique clinique  [Hormone receptors and HER-2 changes during breast cancer progression: clinical implications].
Périodique
Bulletin du Cancer
Auteur(s)
Jacot W., Pouderoux S., Bibeau F., Leaha C., Chateau M.C., Chapelle A., Romieu G.
ISSN
1769-6917 (Electronic)
ISSN-L
0007-4551
Statut éditorial
Publié
Date de publication
2011
Volume
98
Numéro
9
Pages
1059-1070
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Breast cancer remains a major public health problem. Even if there is an increase in this cancer curability, metastatic breast cancer remains a lethal disease in the vast majority of cases. Therapeutic advances in the chemotherapeutic and targeted therapies fields induced an increase in survival, however the proportion of long survivors remains low. Phenotypic instability, an early process initiated during tumour progression, and continued on the metastatic stage of the disease, can be one of the putative hypotheses explaining these results. An increasing amount of scientific data are pledging for a reanalysis of the phenotypic profile regarding hormone receptors and HER-2 status of metastatic lesions in order to identify drugable targets and allow individualisation of the treatment of these metastatic breast cancer patients. Phenotypic changes between the primary tumour and the paired metastatic lymph nodes are a challenging pitfall, raising the question of which site has to be assessed in the adjuvant treatment decision process. This article presents a comprehensive analysis of the frequency of theses phenotypic changes altogether with new modalities to evaluate this phenotypic status.
Mots-clé
Breast Neoplasms/metabolism, Breast Neoplasms/pathology, Disease Progression, Female, Humans, Lymphatic Metastasis, Neoplasm Proteins/metabolism, Neoplasm Recurrence, Local/metabolism, Phenotype, Receptor, erbB-2/metabolism, Receptors, Estrogen/metabolism, Receptors, Progesterone/metabolism
Pubmed
Web of science
Création de la notice
08/02/2012 8:29
Dernière modification de la notice
20/08/2019 12:42
Données d'usage